Phospho-GJA1 (Ser265) Antibody

What is GJA1/Connexin 43 and why is its phosphorylation at Ser265 significant?

Connexin 43 (GJA1) is a key gap junction protein forming channels that allow materials of low molecular weight to diffuse between adjacent cells. It plays critical roles in cellular communication, particularly in cardiac tissue, and participates in potassium recycling in cochlear endolymph, which is essential for hearing physiology . Phosphorylation at serine 265 represents one of several regulatory modifications that can alter gap junction assembly, stability, and channel conductance.

The Ser265 site is located within the C-terminal regulatory domain of Connexin 43, and its phosphorylation status can influence protein-protein interactions, trafficking, and channel gating properties. Understanding this specific phosphorylation event provides insights into the molecular mechanisms that regulate intercellular communication under both physiological and pathological conditions .

What species reactivity can I expect from Phospho-GJA1 (Ser265) antibodies?

Based on available commercial antibodies, Phospho-GJA1 (Ser265) antibodies typically demonstrate reactivity against human, mouse, and rat species . This cross-reactivity is due to the high conservation of the sequence surrounding the Ser265 phosphorylation site across mammalian species. When comparing to related phospho-specific antibodies for GJA1, similar reactivity patterns are observed, such as with phospho-Tyr265 antibodies and phospho-Ser368 antibodies , which also show human, mouse, and rat reactivity.

What applications are Phospho-GJA1 (Ser265) antibodies validated for?

Phospho-GJA1 (Ser265) antibodies are primarily validated for Western Blot (WB) and Enzyme-Linked Immunosorbent Assay (ELISA) applications . These antibodies are typically tested at dilution ranges of 1:500-1:1000 for WB applications . While not explicitly mentioned for this specific antibody, other phospho-specific GJA1 antibodies have also been validated for immunohistochemistry (IHC) , suggesting potential additional applications with proper optimization.

How should I design experiments to differentiate between Ser265 phosphorylation and other phosphorylation sites in GJA1?

Designing experiments to distinguish Ser265 phosphorylation from other phosphorylation sites requires a multi-pronged approach:

• Antibody specificity verification: Compare results using both phospho-specific and total GJA1 antibodies in parallel. The antibodies used have undergone purification to remove non-phospho specific antibodies through chromatography using epitope-specific phosphopeptides .

• Phosphatase controls: Include samples treated with lambda phosphatase to confirm signal specificity to phosphorylated epitopes.

• Competitive peptide blocking: Use synthesized phosphopeptides matching the Ser265 region (Q-K-Y(p)-A-Y) in blocking experiments to confirm antibody specificity.

• Site-directed mutagenesis: Compare wild-type GJA1 with S265A mutants (preventing phosphorylation) to confirm antibody specificity and biological significance.

• Kinase manipulations: Modulate the activity of kinases known to target Ser265 to observe corresponding changes in phosphorylation signal.

This approach helps ensure that observed signals specifically represent Ser265 phosphorylation rather than other phosphorylation sites such as Ser261 , Tyr265 , or Ser368 .

What are the optimal sample preparation methods for detecting Ser265 phosphorylation?

For optimal detection of Ser265 phosphorylation in GJA1, follow these methodological considerations:

• Rapid sample processing: Phosphorylation states can change rapidly; therefore, samples should be processed quickly and kept cold throughout to preserve phosphorylation status.

• Phosphatase inhibitors: Include comprehensive phosphatase inhibitor cocktails in all lysis buffers (e.g., sodium fluoride, sodium orthovanadate, β-glycerophosphate, and pyrophosphate).

• Lysis conditions: Use buffer compositions similar to those used for antibody storage (PBS with phosphatase inhibitors) . Avoid harsh detergents that might disrupt epitope structure.

• Protein denaturation: For Western blotting, denature samples at lower temperatures (70°C instead of 95°C) for shorter durations to minimize potential dephosphorylation.

• Loading controls: Include both total GJA1 controls and housekeeping proteins to normalize phosphorylation levels appropriately.

• Sample types: Cell lysates from gap junction-rich tissues (heart, brain) or cell lines known to express GJA1 (such as K562 cells, which have been used in validation) provide reliable sources for detection.

What controls are essential when using Phospho-GJA1 (Ser265) antibodies?

When conducting experiments with Phospho-GJA1 (Ser265) antibodies, the following controls are essential:

• Positive controls: Lysates from cells or tissues with known high levels of Ser265 phosphorylation, such as K562 cells or cardiac tissue samples.

• Negative controls:

  • Samples treated with lambda phosphatase

  • Samples from Cx43 knockout models or knockdown cells

  • Samples expressing S265A mutant Cx43

• Specificity controls:

  • Use of blocking peptides containing the phosphorylated Ser265 epitope

  • Parallel blots with non-phospho-specific total Cx43 antibodies

  • Pre-absorption controls with phospho and non-phospho peptides

• Loading and transfer controls:

  • Total GJA1 on separate blots (not stripped membranes)

  • Housekeeping proteins (β-actin, GAPDH)

  • Ponceau S staining for total protein normalization

• Antibody controls:

  • Secondary antibody-only controls

  • Isotype controls (rabbit IgG)

These controls help validate that observed signals are specific to phosphorylated Ser265 GJA1 rather than artifacts or non-specific binding.

What are the recommended dilutions and protocols for Western blotting with Phospho-GJA1 (Ser265) antibodies?

For optimal Western blotting with Phospho-GJA1 (Ser265) antibodies:

Recommended dilutions:

• Primary antibody: 1:500-1:1000

• Secondary antibody: Typically 1:5000-1:10000 anti-rabbit HRP conjugate

Protocol optimization:

• Sample preparation: Lyse cells/tissues in buffer containing phosphatase inhibitors

• Protein loading: 20-40 μg total protein per lane

• Gel percentage: 10-12% SDS-PAGE gels for optimal separation of the 43 kDa GJA1 protein

• Transfer conditions: Semi-dry or wet transfer at 100V for 60-90 minutes

• Blocking: 5% BSA in TBST (not milk, which contains phosphatases) for 1 hour at room temperature

• Primary antibody incubation: Diluted in 5% BSA/TBST, overnight at 4°C

• Washing: 3-5 times with TBST, 5-10 minutes each

• Secondary antibody: Anti-rabbit HRP, 1 hour at room temperature

• Detection: ECL substrate with expected molecular weight of approximately 43 kDa

For challenging samples or weak signals, consider signal enhancement systems or increasing antibody concentration to 1:250.

How can I optimize ELISA protocols using Phospho-GJA1 (Ser265) antibodies?

For ELISA applications with Phospho-GJA1 (Ser265) antibodies:

Recommended dilutions:

• For direct ELISA: 1:5000 primary antibody dilution is a good starting point, similar to other phospho-GJA1 antibodies

Protocol considerations:

• Coating: Use purified GJA1 protein or synthetic phosphopeptides at 1-10 μg/ml in carbonate buffer (pH 9.6)

• Blocking: 2-5% BSA in PBS or TBS (avoid milk proteins)

• Sample preparation: Prepare cell/tissue lysates with phosphatase inhibitors

• Antibody diluent: Use diluent similar to storage buffer (PBS with 0.5% BSA)

• Incubation: 1-2 hours at room temperature or overnight at 4°C

• Detection system: HRP-conjugated anti-rabbit secondary antibody followed by TMB substrate

• Standard curve: Include serial dilutions of phosphorylated peptide as standards

• Controls: Include non-phosphorylated peptide controls and phosphatase-treated samples

For sandwich ELISA, capture with total GJA1 antibody and detect with phospho-specific antibody for increased specificity in complex samples.

How can I troubleshoot weak or non-specific signals when using Phospho-GJA1 (Ser265) antibodies?

When encountering issues with Phospho-GJA1 (Ser265) antibody experiments, consider these troubleshooting approaches:

For weak signals:

• Increase antibody concentration: Try more concentrated primary antibody (1:250 instead of 1:500)

• Extend incubation time: Overnight at 4°C instead of 1-2 hours

• Enhance detection: Use high-sensitivity ECL substrates or signal amplification systems

• Increase protein loading: Load 50-60 μg total protein instead of 20-30 μg

• Optimize sample preparation: Ensure phosphatase inhibitors are fresh and effective

• Enrich target protein: Consider immunoprecipitation before Western blotting

For non-specific signals:

• Increase blocking stringency: 5% BSA with 0.1-0.3% Tween-20

• Add competitive blockers: 2-5% normal serum from secondary antibody species

• Optimize washing: Increase number and duration of washes

• Reduce antibody concentration: Try more dilute antibody solutions

• Pre-clear lysates: Incubate with protein A/G beads before immunoblotting

• Filter antibody: Centrifuge antibody solution before use to remove aggregates

For high background:

• Fresh buffers: Prepare fresh blocking and washing buffers

• Clean membranes: Handle membranes with clean forceps only

• Filter reagents: Filter all solutions to remove particulates

• Optimize blocking: Try alternative blockers like casein or commercial blockers

How should I analyze and quantify phosphorylation data from Western blots using these antibodies?

For rigorous quantification of Phospho-GJA1 (Ser265) Western blot data:

• Normalization approaches:

  • Normalize phospho-GJA1 signal to total GJA1 signal from parallel blots

  • Additionally normalize to loading controls (β-actin, GAPDH)

  • Consider total protein normalization (Ponceau S, Coomassie)

• Quantification method:

  • Use densitometry software (ImageJ, Image Lab, etc.)

  • Measure integrated density rather than peak intensity

  • Subtract local background from each band

• Statistical analysis:

  • Run at least three biological replicates

  • Use appropriate statistical tests (t-test for two conditions, ANOVA for multiple)

  • Report data as fold change relative to control condition

  • Include error bars representing standard deviation or SEM

• Data presentation:

  • Show representative blot images alongside quantification graphs

  • Include molecular weight markers on images

  • Present both phospho-GJA1 and total GJA1 data

  • Report p-values for statistical significance

• Controls integration:

  • Include quantification of positive and negative controls

  • Show phosphatase-treated control effects quantitatively

This approach ensures reliable quantitative assessment of changes in Ser265 phosphorylation levels across experimental conditions.

How can I study the relationship between Ser265 phosphorylation and other GJA1 phosphorylation sites?

To investigate the interplay between Ser265 and other phosphorylation sites on GJA1:

• Sequential immunoprecipitation:

  • First IP with one phospho-specific antibody

  • Western blot precipitate with antibody against second phospho-site

  • This reveals proportion of GJA1 with both modifications

• Multi-phosphorylation analysis:

  • Compare phosphorylation patterns after stimulating various kinase pathways

  • Use phospho-specific antibodies against Ser261 , Tyr265 , Ser368 , and Ser265 in parallel

  • Analyze temporal relationships between different phosphorylation events

• Site-directed mutagenesis approaches:

  • Create single and multiple phosphosite mutants (S265A, S368A, etc.)

  • Examine how mutation at one site affects phosphorylation at others

  • Analyze functional consequences of different mutation combinations

• Mass spectrometry:

  • Perform phosphopeptide mapping of immunoprecipitated GJA1

  • Quantify relative abundance of different phosphorylated peptides

  • Identify novel phosphorylation patterns and combinations

• Phosphatase/kinase manipulations:

  • Use site-specific kinase inhibitors to examine phosphorylation interdependence

  • Apply mathematical modeling to understand phosphorylation site interactions

This multi-faceted approach can reveal whether Ser265 phosphorylation occurs independently of or in concert with other modifications, providing insights into the complex regulation of GJA1 function.

What is known about the kinases responsible for GJA1 Ser265 phosphorylation?

The specific kinases targeting Ser265 in GJA1 include:

• Candidate kinases:

  • Based on the sequence context around Ser265 (Q-K-Y-A-Y) , proline-directed kinases like MAPK family members are potential candidates

  • Casein kinase 1 (CK1) has been implicated in phosphorylating serine residues in the C-terminal domain of Connexin 43

  • Protein kinase C (PKC) may indirectly influence Ser265 phosphorylation through signaling cascades

• Experimental approaches to identify responsible kinases:

  • In vitro kinase assays with purified kinases and GJA1 peptides

  • Kinase inhibitor screens using phospho-Ser265 antibody readouts

  • RNA interference of candidate kinases followed by phosphorylation analysis

  • CRISPR/Cas9 knockout of candidate kinases

• Physiological contexts:

  • Investigate phosphorylation status after activating specific signaling pathways

  • Compare phosphorylation patterns in different tissues and cell types

  • Examine phosphorylation during development and in disease models

• Verification methods:

  • Co-immunoprecipitation of GJA1 with candidate kinases

  • Proximity ligation assays to detect kinase-substrate interactions

  • Phosphoproteomic analysis after kinase activation/inhibition

Understanding the kinases responsible for Ser265 phosphorylation will provide insight into the signaling pathways regulating gap junction communication and potential therapeutic targets for diseases involving dysregulated intercellular communication.

What are the optimal storage and handling conditions for maintaining antibody activity?

To preserve the activity and specificity of Phospho-GJA1 (Ser265) antibodies:

• Storage temperature:

  • Store at -20°C for long-term storage

  • For frequent use, aliquots can be kept at 4°C for up to one month

• Buffer conditions:

  • Antibodies are typically supplied in PBS containing 50% glycerol, 0.5% BSA, and 0.02% sodium azide

  • This formulation helps maintain stability during freeze-thaw cycles

• Aliquoting recommendations:

  • Upon receipt, divide into small working aliquots (10-20 μl)

  • Use sterile microcentrifuge tubes

  • Label with antibody name, concentration, date, and dilution recommendations

• Freeze-thaw considerations:

  • Avoid repeated freeze-thaw cycles as they can compromise antibody activity

  • Thaw aliquots at room temperature or on ice, never at high temperatures

• Working dilution handling:

  • Prepare working dilutions fresh on the day of experiment

  • Keep diluted antibody on ice during experiment

  • Do not store diluted antibody for extended periods

• Contamination prevention:

  • Use sterile technique when handling

  • Avoid introducing bacteria or fungi which can degrade antibodies

  • Include 0.02% sodium azide in storage buffer as preservative